ANALYZING THE TREATMENT COST OF LIVER CIRRHOSIS FROM HEALTHCARE PAYER'S PERSPECTIVE OF VIETNAM IN 2015

被引：1
|
作者：
Nguyen, D. K. [1 ]
Nguyen, T. T. [2 ]
Pho, N., V [1 ]
机构：
[1] Univ Med & Pharm, Ho Chi Minh City, Vietnam
[2] Univ Med & Pharm HCMC, Ho Chi Minh City, Vietnam
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1429
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI11
引用
收藏
页码：A633 / A633
页数：1
相关论文
共 50 条
  • [21] Impact of age on healthcare costs and resource utilization in patients with Crohn's disease from a payer perspective
    Dabbous, O.
    Thompson, H.
    Arjunji, R.
    Tang, B.
    Gdovin, J.
    Rahman, M. I.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S414 - S414
  • [22] Impact of age on healthcare costs and resource utilization in patients with Crohn's disease from a payer perspective
    Dabbous, O.
    Thompson, H.
    Arjunji, R.
    Tang, B.
    Gdovin, J.
    Rahman, M.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 660 - 660
  • [23] COST IMPLICATIONS OF RESTRICTING PALONOSETRON UTILIZATION FOR THE TREATMENT OF CINV: RESULTS FROM AN ANALYTIC MODEL FROM A PAYER PERSPECTIVE
    Powers, A.
    Sarnes, E.
    Knoth, R. L.
    Balu, S.
    Buchner, D.
    VALUE IN HEALTH, 2010, 13 (07) : A257 - A257
  • [24] Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
    Tsai, Naoky
    Jeffers, Lennox
    Cragin, Lael
    Sorensen, Sonja
    Su, Wenqing
    Rosenblatt, Lisa
    Tang, Hong
    Hebden, Tony
    Juday, Timothy
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 227 - 235
  • [25] COST EFFECTIVENESS OF ONABOTULINUMTOXINA VERSUS PTNS AND SNS FOR THE TREATMENT OF OVERACTIVE BLADDER FROM THE US PAYER PERSPECTIVE
    Hepp, Z.
    Yehoshua, A.
    Gultyaev, D.
    Lister, J.
    VALUE IN HEALTH, 2016, 19 (03) : A130 - A130
  • [26] EVOLUTION OF CANCER TREATMENT COST IN THE LAST 36 MONTHS: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL
    Reis Neto, J. P.
    Busch, J.
    VALUE IN HEALTH, 2023, 26 (06) : S391 - S391
  • [27] COST OFFSET AND BUDGET IMPACT OF SKYTROFA FOR THE TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY: A US PAYER'S PERSPECTIVE
    Smith, A. R.
    Noori, W.
    Raveendran, S.
    Kleintjens, J.
    Boller, E.
    VALUE IN HEALTH, 2023, 26 (12) : S83 - S83
  • [28] Documenting the Benefits and Cost Savings of a Large Multistate Cancer Pathway Program From a Payer's Perspective
    Kreys, Eugene D.
    Koeller, Jim M.
    JOURNAL OF ONCOLOGY PRACTICE, 2013, 9 (05) : E241 - E247
  • [29] COST-EFFECTIVENESS OF PHARMACOTHERAPIES FOR TREATMENT NAIVE HEPATITIS C GENOTYPE 1 PATIENTS: A PAYER'S PERSPECTIVE
    Jalundhwala, Y. J.
    Manzoor, B. S.
    Patel, H.
    Cheng, W. H.
    Patel, P.
    Touchette, D. R.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [30] A Payer's Perspective on the Cost-Effectiveness of Gastric Bypass Surgery REPLY
    Ikramuddin, Sayeed
    Swan, Therese
    Klingman, C. David
    Minshall, Michael E.
    AMERICAN JOURNAL OF MANAGED CARE, 2009, 15 (11): : 828 - +
12345